Predict your next investment

Venture Capital
negevcap.com

See what CB Insights has to offer

Investments

6

About Negev Capital

Negev Capital primarily targets companies with medications that are at an early stage of clinical development.

Negev Capital Headquarter Location

Ugland House

Grand Cayman, KY1-1104,

Cayman Islands

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Negev Capital News

Negev Capital, a Psychedelic Medical Intervention Investment Fund to Exhibit at Nov. 8-9, 2021 Wonderland Miami Conference

Nov 3, 2021

By Reading Time: 2 minutes Toronto, Ontario–(Newsfile Corp. – November 3, 2021) – Negev Capital, a psychedelic medical intervention investment fund will present at the inaugural psychedelic medicine real-world event Wonderland Miami, Nov. 8-9, 2021 at the Adrienne Arsht Center for the Performing Arts in Miami. The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business. Among Wonderland: Miami’s impressive group of global psychedelic medicine leaders, scientists and researchers, investors and entrepreneurs, therapists and patients, government officials and media, Ken Belotsky, Negev Capital’s partner will join the conference line up. The fund will also host private meetings in activation room number 3016. Ken Belotsky, Negev Capital’s partner, is participating in the Finance and Psychedelics Panel on Tuesday, November 9th at 10:10 am. Where: Adrienne Arsht Center for the Performing Arts, 1300 Biscayne Blvd, Miami, FL 33132 Details: Ken Belotsky, Negev Capital’s partner will discuss Finance and Psychedelics with other leading VC’s in the space Can consciousness and capitalism coexist? ”Wonderland Miami is championing the growth of the psychedelic medicine industry. We look forward to meeting in person.” – Ken Belotsky, Negev Capital, Partner. For more information, please visit https://microdose.buzz/wonderland/ . This press release (i) is not an offer, or solicitation of an offer to buy or sell any security or investment, and (ii) does not constitute tax, legal or investment advice. Notes to Editor About Negev Capital Negev Capital is a psychedelic medical intervention investment fund with assets of USD$25+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP. We believe that psychedelic medications will be not only disruptive to the practice of psychiatry, but hold the potential to reduce enormous amounts of human suffering, and we are committed to helping the field mature, and further promote ways for these treatments to reach all of those in need. For further information, please visit https://negevcap.com/ Contacts

Negev Capital Investments

6 Investments

Negev Capital has made 6 investments. Their latest investment was in Clairvoyant Therapeutics as part of their Seed VC on November 11, 2021.

CBI Logo

Negev Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/30/2021

Seed VC

Clairvoyant Therapeutics

$2.34M

Yes

Ambria Capital, Iter Investments, and Undisclosed Investors

2

10/12/2021

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

9/27/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

8/16/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/7/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/30/2021

10/12/2021

9/27/2021

8/16/2021

7/7/2021

Round

Seed VC

PIPE

Series A

Series B

Seed VC

Company

Clairvoyant Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.34M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Ambria Capital, Iter Investments, and Undisclosed Investors

Sources

2

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.